Free Trial

Absci Q3 2023 Earnings Report

Absci logo
$4.96 -0.24 (-4.53%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Absci EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Absci Revenue Results

Actual Revenue
$0.74 million
Expected Revenue
$3.01 million
Beat/Miss
Missed by -$2.27 million
YoY Revenue Growth
N/A

Absci Announcement Details

Quarter
Q3 2023
Time
N/A

Absci Earnings Headlines

Absci Co. (NASDAQ:ABSI) Sees Large Decline in Short Interest
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
Traders Purchase Large Volume of Absci Call Options (NASDAQ:ABSI)
See More Absci Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Absci? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Absci and other key companies, straight to your email.

About Absci

Absci (NASDAQ:ABSI) operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

View Absci Profile

More Earnings Resources from MarketBeat